2nd Aug 2005 17:11
2 August 2005Shire Pharmaceuticals Group plc (the "Company")Notification of Grant of Options to Persons Discharging ManagerialResponsibilitiesThe Company announces that on 1 August 2005 the following options were grantedover ordinary shares of ‚£0.05p each in the capital of the Company pursuant tothe rules of the Shire Pharmaceuticals Group plc 2000 Executive Share OptionScheme (the "Scheme") as follows:1. Mr Michael Cola was granted options over 250,000 ordinary shares atan exercise price of ‚£6.515 upon his joining the Company. Mr Cola is ExecutiveVice President for Global Therapeutic Area Business Units and a member of theCompany's Executive Committee. The face value of the grant is approximatelythree times Mr Cola's base salary (which is the standard level of grant fornew members of the Executive Committee) plus additional options to compensateMr Cola for unvested shares and options in his former employer that he wasunable to exercise when leaving that company. 2. Mr David Pendergast was granted options over 150,000 ordinary sharesat an exercise price of ‚£6.515 upon his joining the Company. Mr Pendergast wasCEO of Transkaryotic Therapies, Inc which merged with Shire on 27 July 2005. Mr Pendergast has joined the Company and its Executive Committee as ExecutiveVice President and General Manager. The face value of the grant isapproximately three times Mr Pendergast's base salary (the standard level ofgrant for new members of the Executive Committee) .3. Ms Tatjana May was granted options over 20,000 shares at an exerciseprice of ‚£12.57. These options were offered to Ms May when she joined theCompany in 2001 but, due to an administrative error, were not formally grantedto her.All grants are subject to performance conditions under the rules of the ShirePharmaceuticals Group plc 2000 Executive Share Option Scheme.ENDSHIRE PHARMACEUTICALS GROUP PLCRelated Shares:
Shire